anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SCOPE: Metabolic syndrome (MetS) significantly contributes to premature mortality, with obesity being a major risk factor. Dragon fruit, cultivated globally, exhibits bioactivity in preventing obesity-related diseases. Traditional studies using organic solvents for extraction do not align with actual consumption patterns.
METHOD AND RESULTS: This study evaluates whole red dragon fruit's effectiveness in ameliorating metabolic disorders using a high-fat diet-induced obesity model in mice for 20 weeks. The experimental groups include the supernatant (RS), precipitate (RP), and pomace (PO) of red dragon fruit juice, compared to the supernatant of white dragon fruit juice (WS). The study finds that dragon fruit extracts reduced adipose tissue weight, body fat percentage, pro-inflammatory cytokines, and improved blood lipid profiles. RP is the most effective, reducing body weight by 4.33 g, improving lipid metabolism and glucose homeostasis, and altering gut microbiota to enhance beneficial bacteria and short-chain fatty acids. RP's efficacy in preventing MetS and obesity is attributed to its bioactive components.
CONCLUSION: These findings advocate for using whole fruits in developing functional products, amplifying the agricultural economic value of red dragon fruit.
PURPOSE:To selectively carry out the binding of a cell to a polymer utilizing a difference in a Km value for all the cells taking in glucose as an energy source by using a glucose transporter as a binding site. CONSTITUTION:A cell having a glucose transporter (e.g. an erythrocyte, HepG2 or a cell of a brain, the kidney, the colon, etc., having Glut1) is inoculated onto, e.g. a polymer, having the affinity for the glucose transporter (preferably a polymer having a residue in the side chain, more preferably a polymer in which the reducing terminal of the glucose residue is not used for binding, e.g. a polymer of formula I, II, etc.) and adsorbed or chemically bound to a culture substrate.
One examination with TCD baseline and with NIRS baseline, and a second examination with TCD after bosentan administration and with NIRS after bosentan administration will be performed; The examination will be repeated only in the patients with MS (i.e. not in control subjects) 4 h after the oral intake of one tablet 62.5 mg bosentan (Tracleer®) (when peak plasma concentrations are expected).
Necroptosis is a kind of programmed cell death that causes the release of damage-associated molecular patterns and inflammatory disease including skin inflammation. Activation of receptor-interacting serine/threonine kinase 1 (RIPK1), RIPK3, and mixed lineage kinase domain-like protein (MLKL) is the hallmark of tumour necrosis factor α (TNF)-induced necroptosis. Here, we screened a small-molecule compound library and found that saracatinib inhibited TNF-induced necroptosis. By targeting MLKL, Saracatinib interfered with the phosphorylation, translocation, and oligomerization of MLKL induced by TNF. Consistently, mutation of the saracatinib-binding site of MLKL reduced the inhibitory effect of saracatinib on TNF-induced necroptosis. In an imiquimod (IMQ)-induced psoriasis mouse model, saracatinib effectively blocked MLKL phosphorylation and inflammatory responses in vivo. Taken together, these findings indicate that saracatinib inhibits necroptosis by targeting MLKL, providing a potential therapeutic approach for skin inflammation-related diseases such as psoriasis.
The effectiveness of LUNESTA was established in five controlled studies in chronic insomnia. Three controlled studies were in adult subjects, and two controlled studies were in elderly subjects with chronic insomnia. 

Adults

In the first study, adults with chronic insomnia (n=308) were evaluated in a double-blind, parallel-group trial of 6 weeks' duration comparing LUNESTA 2 mg and 3 mg with placebo. Objective endpoints were measured for 4 weeks. Both 2 mg and 3 mg were superior to placebo on LPS at 4 weeks. The 3 mg dose was superior to placebo on WASO. 

In the second study, adults with chronic insomnia (n=788) were evaluated using subjective measures in a double-blind, parallel-group trial comparing the safety and efficacy of LUNESTA 3 mg with placebo administered nightly for 6 months. LUNESTA was superior to placebo on subjective measures of sleep latency, total sleep time, and WASO. 

In addition, a 6-period crossover PSG study evaluating eszopiclone doses of 1 to 3 mg, each given over a 2-day period, demonstrated effectiveness of all doses on LPS, and of 3 mg on WASO. In this trial, the response was dose related. 

Elderly

Elderly subjects (ages 65-86 years) with chronic insomnia were evaluated in two double-blind, parallel-group trials of 2 weeks duration. One study (n=231) compared the effects of LUNESTA with placebo on subjective outcome measures, and the other (n=292) on objective and subjective outcome measures. The first study compared 1 mg and 2 mg of LUNESTA with placebo, while the second study compared 2 mg of LUNESTA with placebo. All doses were superior to placebo on measures of sleep latency. In both studies, 2 mg of LUNESTA was superior to placebo on measures of sleep maintenance.
Patients recruited for phase 3 will complete the draft questionnaire, and rate each item for relevance, and indicate the 10 most important items. Also, a semi-structured interview will be conducted including debriefing questions to determine if the questionnaire is complete and the questions are acceptable.
Approximately 22% of substance users suffer from elevated depressive symptoms, which is associated with higher rates of substance abuse treatment dropout, relapse to substance use, and HIV risk behavior. Few interventions targeting reinforcement principles have been developed to meet the specific needs of treatment seeking substance users. One approach that may be especially appropriate in this regard is behavioral activation (BA), which aims to increase individuals' engagement in pleasant events, thereby increasing contact with positive reinforcement and decreasing the frequency of aversive events. BA has been shown to be efficacious in the treatment of depression, and this uncomplicated and straightforward approach may be especially appropriate for the specific needs of an inner city low income substance abusing sample. Further, BA compliments standard substance abuse treatment in several key practical and theoretical ways as it is more easily adopted by staff in these settings, more time efficient (e.g., fewer and shorter sessions, group format), more easily understood by patients who suffer from cognitive limitations due to low education level and chronic drug use, and can incorporate aspects of sobriety into its treatment components. In an initial Stage 1 development project, a version of BA, the Life Enhancement Treatment for Substance Use (LETS ACT), was developed and specifically tailored for inner-city low income minority substance users with elevated depressive symptoms. Results demonstrated that LETS ACT led to a significantly greater reduction in self-reported depressive symptoms and a significant increase in enjoyment and reward value of activities as compared to the TAU control group (Daughters et al., 2008). While preliminary findings prove promising, many questions remain unanswered and several extensions of this work are necessary, including an assessment of post treatment substance use and HIV risk behavior, a contact-matched control, and a larger sample size to allow for more complex analyses of the mechanisms underlying these outcomes. Thus, the objective of the present proposal is to follow-up on our previous Stage 1 treatment development efforts and small scale randomized control trial (RCT) with a fully-powered Stage 2 RCT comparing LETS ACT to nondirective therapy (NDT) among a sample of 263 low income depressed substance users currently receiving residential substance abuse treatment in inner-city Washington, DC.
Live attenuated bovine-human \[UK\] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
A process is provided for infusing a cannabis storage container with a terpene composition. The process injects a pre-fabricated aroma emission device with the terpene composition. The pre-fabricated aroma emission device has one or more pores through which an aroma from the terpene composition is emitted. Further, the process positions the pre-fabricated aroma emission device within the cannabis storage container. Additionally, the process seals the cannabis storage container. The pre-fabricated aroma emission device emits the aroma of the terpene composition through the one or more pores without human activation after said sealing of the cannabis storage container. Alternatively, a process for manufacture is provided for manufacture of an aroma emission device.
Cognitive solutions are provided for detection of, and optimization based on, cohorts, arms, and phases in clinical trials. In various embodiments, a first datastore is accessed. The first datastore comprises a clinical trial description. The clinical trial description includes a reference to a cohort, arm, or phase of a clinical study. The clinical trial description is analyzed to identify an entity type. The entity type is a cohort, arm or phase reference. A clinical attribute associated with the entity type is determined within the clinical trial description. A screening criterion associated with the clinical attribute is determined. A second datastore is accessed. The second datastore comprises a medical record of a patient. The medical record is screened against the screening criterion.
The ACT evaluates how well asthma affects daily functioning, and overall asthma control self-assessment. The score ranges from 5 (poor control of asthma) to 25 (well control of asthma). An ACT score \>19 indicates well-controlled asthma.
PURPOSE:A cosmetic obtained by incorporating an allantoin and an L-ascorbic acid together therein, and capable of enhancing synergistically the effect on improvement in skin roughening. CONSTITUTION:A cosmetic containing at least one or more selected from the group consisting of allantoin expressed by the formula and derivatives thereof, e.g. dihydroxyaluminum allantoate, and at least one or more selected from the group consisting of L-ascorbic acid and esters thereof, e.g. L-ascorbic acid monostearate. The cosmetic containing the allantoin and L-ascorbic acid, etc. has effect on prevention of skin roughening, curing wounds and beautification and whitening, etc. The use of both together increases synergistically the effect on improvement in the skin roughening. The amounts of the components to be incorporated are as follows: 0.001-5.0wt%, preferably 0.05-3.0wt% allantoin and >=0.001wt%, preferably about 10.0wt% L-ascorbic acid.
The invention provides a dandelion acne-removing and skin-nourishing mask and a preparing method of the dandelion acne-removing and skin-nourishing mask, and relates to an acne-removing and skin-nourishing mask and a preparing method of the acne-removing and skin-nourishing mask. The invention aims at solving the problems that the existing mask has the potential safety hazards; the serious skin problem can be easily caused; and the problems of dark and rough skin, cutis laxa and fine wrinkle cannot be solved. The dandelion acne-removing and skin-nourishing mask is prepared from dandelion, fructus forsythiae, angelica dahurica, roses, clove, pearl powder and honey. The preparing method comprises the following steps of 1, crushing the dandelion, the fructus forsythiae, the angelica dahurica, the roses, the clove and the pearl powder by a crushing machine; sieving the materials by a 120-mesh sieve; and then, uniformly stirring the materials to obtain mixed medicine powder; and 2, slowly adding distilled water and the honey into the mixed medicine powder; stirring the mixture into paste; and obtaining the dandelion acne-removing and skin-nourishing mask. After the mask is used for a long time, the skin can be soft, bright, clean, white, tender and fine; and the mask has the advantages of obvious effect and low cost. The preparing method is applied to the field of preparation of the acne-removing and skin-nourishing mask.
Intensive treatment group in 24 hours: Patients in this group will receive periodontal treatment including: plaque control instructions, supragingival and subgingival debridement and scaling and root planing. This treatment is carried out in 2 sessions within 24 hours. In the first session hygiene instruction and supragingival and scaling and root planing of the teeth in right side at the upper jaw and mandible will be performed. The implementation of each upper and lower hemiarcade will be made until the periodontist treating check manually the removal of all subgingival calculus deposit and feel the smoothness of the root surface. In the second session, there will be an identical procedure in the arch left.
The invention relates to a drug for curing diabetes, which is prepared from root-bark of Chinese wolfberry, ramulus euonymi, coptis chinensis and dogwood according to weight proportion. The preparation method of the drug is as below: firstly, immersing the prescribed bulk drugs with water, and then carrying out decoction and filtration; adding water into decoction dregs, and then carrying out decoction and filtration; combining filtrates obtained from the two times of decocting; depressurizing and concentrating the combined filtrate into an extract with 3g of crude drug per milliliter; and obtaining the drug. As being demonstrated by pharmacologic tests, the drug can obviously reduce blood sugar content of a model mouse. The drug is developed based on the study on prescriptions of 2000 patients. The cause of the diabetes is the interaction of dryness-heat, moist heat and stagnant heat, and the root cause of the diabetes is deficiency of qi and yin as well as hepatic and renal deficiency. Based on the cause and the root cause, the invention provides a theory of traditional Chinese medical science, i.e. to adopt a three-heat theory to cure the diabetes. In the prescription, the root-bark of Chinese wolfberry is used for clearing the dryness-heat; the coptis chinensis is used for clearing the moist heat; the ramulus euonymi is used for clearing the stagnant heat; and dogwood is used for tonifying yin and qi; therefore, the aim of addressing both the symptoms and root causes is achieved.
FIELD: medicine. ^ SUBSTANCE: invention relates to the field of veterinary. Method includes single subcutaneous introduction of vaccine against paraflu-3 and infectious cattle rhinotracheitis dry cultural live in dose 2 ml to cows 1.5 month before delivery. Additionally cows are immunized with Coli-Vac K99 vaccine, intramuscularly, in dose 10 cm3 and 10-15 days after that in dose - 15 cm3. 15-60 minutes after birth 5% glucose solution in dose 1 ml/kg of body weight, 5% ascorbic acid solution in dose 2 ml per animal and intramuscularly 5% unitiole solution in dose 1 ml/10 kg of body weight are simultaneously introduced to newborn calves obtained from said cows. ^ EFFECT: method contributes to formation of more intense colostral immunity in newborn calves with low viability in comparison with analogues. ^ 12 tbl, 2 ex
NEW MATERIAL:The extract obtained by extracting the bark of Japanese bead tree woth water or a polar organic solvent at room temperature as pretreatment, and then extracting the extraction residue with hot water. USE:An anti-malignant neoplastic agent, especially antitumor agent. PROCESS:The bark of Japanese bead tree (e.g. Melia azedarach L., Melia azedarach L. var toosendan, etc.) is dried, chopped, and extracted with water or a polar organic solvent such as alcohol, acetone, etc. at room temperature (0- 40 deg.C) as the pretreatment. The resultant extraction residue is extracted by adding hot water thereto or adding cold water and boiling the mixture, and the extract is dried by concentration to dryness, freeze, etc. The hot-water extract can be purified by precipitating with an alcohol or by treating with a dialyzing membrane.
Bile acids are microbial metabolites that can impact infection of enteric and hepatitis viruses, but their functions during systemic viral infection remain unclear. Here we show that elevated levels of the secondary bile acid taurolithocholic acid (TLCA) are associated with reduced fatality rates and suppressed viraemia in patients infected with severe fever with thrombocytopenia syndrome virus (SFTSV), an emerging tick-borne haemorrhagic fever virus. TLCA inhibits viral replication and mitigates host inflammation during SFTSV infection in vitro, and indirectly suppresses SFTSV-mediated induction of ferroptosis by upregulating fatty acid desaturase 2 via the TGR5-PI3K/AKT-SREBP2 axis. High iron and ferritin serum levels during early infection were correlated with decreased TLCA levels and fatal outcomes in SFTSV-infected patients, indicating potential biomarkers. Furthermore, treatment with either ferroptosis inhibitors or TLCA protected mice from lethal SFTSV infection. Our findings highlight the therapeutic potential of bile acids to treat haemorrhagic fever viral infection.
Fatty liver, which is induced by abnormal lipid metabolism, is one of the most common causes of chronic liver disease globally and causes liver fibrosis. During this process, bone marrow-derived mesenchymal stromal cells (BMSCs) and hepatic stellate cells (HSCs) migrate toward the injured liver and participate in fibrogenesis by transdifferentiating into myofibroblasts. S100A8/A9 is a powerful inducer of cell migration and is involved in liver injury. But there are few reports about the effects of S100A8/A9 on BMSC/HSC migration. In the current study, we found that S100A8/A9 expression was increased during fatty liver injury/fibrogenesis. Moreover, S100A8/A9 expression had a positive correlation with fibrosis marker gene expressions in the injured liver. S100A8/A9 was mainly produced by neutrophils in the fibrotic liver. In vitro, neutrophil-secreted S100A8/A9 promoted BMSC/HSC migration via remodeling of microfilaments. Using specific siRNA and inhibitor, we proved that S100A8/A9-induced BMSC/HSC migration is dependent on TLR4/Rho GTPases signaling. Moreover, S100A8/A9 knock-down alleviated liver injury and fibrogenesis in vivo, while injection of S100A9 neutralizing antibody performed similar roles. We proved that S100A8/A9 was involved in liver injury and fibrogenesis via inducing BMSC/HSC migration. Our research reveals a new mechanism underlying BMSC/HSC migration in liver fibrosis and suggests S100A8/A9 as a potential therapeutic target of liver fibrosis. KEY MESSAGES: S100A8/A9 is secreted by neutrophils and increased in fatty liver injury. Neutrophil-secreted S100A8/A9 is a mediator of BMSC/HSC migration in vitro. S100A8/A9-induced BMSC/HSC migration is dependent on TLR4/Rho GTPases signaling. S100A8/A9 blockade alleviates liver injury and fibrogenesis in vivo.
Methods of modulating thrombin-mediated platelet activation by inhibition or  enhancement of protease-activated receptor 4(PAR4) and protease-activated receptor 1(PAR1) activity are disclosed. This method provides a way of substantially blocking all thrombin-mediated activation of platelets by 1) inhibiting signalling though PAR1 and 2) inhibiting signalling through PAR4.  Signalling through each PAR receptor may be inhibited at various molecular levels, including: the level of ligand binding (e.g.by administration of an antagonist), the level of the receptor activity (e.g. blocking expression of the receptor in the relevant cells) and/or intracellularly, (e.g.blocking expression or activity of a molecule required for activity of the receptor). Alternatively, this method provides a method for enhancing thrombin-mediated platelet activation by specifically activating PAR1 and PAR4. These methods may take place in vivo, through administration of the appropriate compounds, or in vitro, e.g.the ex vivotreatment of a sample.
Antithrombotic therapy and percutaneous or surgical myocardial revascularization procedures are the basis of the treatment of patients admitted with non-ST-segment elevation acute coronary syndrome. However, the desired reduction of the recurrence of ischemic events has as complication an increased incidence of bleeding. Since arterial puncture followed by the insertion of an introducer has become the standard method to perform invasive cardiovascular procedures, complications related to vascular access have become an important bleeding site.

Among the strategies to decrease vascular complications, the transradial approach is a well stablished alternative to the transfemoral approach. For its part, vascular closure devices were introduced to decrease vascular complications, homeostasis time and ambulation time of patients submitted to invasive procedures by the transfemoral access. Rapidly incorporated to the clinical practice, such devices to date have shown conflicting results with regard to their safety and efficacy. The inconsistency of data proving its safety limits its routine adoption as strategy to prevent vascular complications, requiring evidences through adequately designed randomized studies for this end.
FIELD: natural proteins, pharmacy. SUBSTANCE: invention relates to method of stabilization of hirudine or hirudine variants containing the sequence - Asp-Gly- or Asn-Gly-. Method involves the controlled exchange of the sequence -Asp-Gly- or Asn-Gly- for succinimide fragment or β-rearranged fragment. Invention relates to also the hirudine-containing lyophilized pharmaceutical composition exhibiting the excellent stability as result of stabilizing method to be proposed. Method of stabilization of this peptide involves addition of an organic acid, bringing about pH value of this peptide to 5.0- 6.5 and lyophilization of mixture prepared. Desulfated hirudine or variant of hirudine are used as peptide. Sucrose, mannitol and related substances can be added apart from this organic acid. Invention provides the effective preservation of hirudine in prolonged storage. EFFECT: improved method of stabilization, improved properties of composition. 14 cl, 8 tbl, 6 ex
People with scores above 12 on the EPDS have a 10 times greater likelihood of having a diagnosis of depression than those with scores with 12 or less, so this is an appropriate cut-off. The primary endpoint is at 12 weeks post-randomization and the secondary endpoint is at 24 weeks post-randomization. Randomization will be performed as block randomization (varying block sizes) with a 1:1 allocation and will be stratified based on EPDS score (13-19 vs. 20 or greater). Participants who score 12 or less on the EPDS in their initial self-referral screen will be informed that they are not at high risk for having depressive or anxiety disorder and the current time, and can re-screen as needed. Participants whose score is in the 9-12 range (i.e. those who are not likely to be experiencing a depressive or anxiety disorder requiring mental health treatment, but might benefit from additional support) will receive an automated message that communicates their score and the acknowledgment of their possible need for support, and provides a list of resources in Ontario that may be helpful for them. These participants will be invited to re-screen at any time into the study, and will be asked permission to be re-contacted in future to determine which supports they used, if any.